01672.HK
Ascletis Pharma Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 10.09
−2.32%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.3M | 2.0M | 1.3M | 56.6M | 54.1M |
| Cost of Revenue | 10.6M | 1.5M | 548.0K | 30.6M | 78.8M |
| Gross Profit | (7.3M) | 527.0K | 735.0K | 26.0M | (24.7M) |
| Operating Expenses | |||||
| R&D Expense | 913.4M | 409.1M | 302.4M | 216.8M | 267.1M |
| SG&A Expense | 165.5M | 75.2M | 101.7M | 63.0M | 32.4M |
| General & Admin Expense | 135.6M | 75.2M | 101.7M | 62.6M | 15.4M |
| Selling & Marketing Expense | — | — | — | 387.0K | 17.0M |
| Other Expenses | 65.8M | — | (108.0M) | (129.5M) | 19.8M |
| Total Operating Expenses | 1.1B | 484.3M | 296.2M | 150.3M | 319.3M |
| Cost and Expenses | 1.2B | 485.8M | 296.7M | 180.9M | 398.1M |
| Operating Income (EBIT) | (1.2B) | (483.8M) | (295.4M) | (300.2M) | (344.0M) |
| Non-Operating | |||||
| Interest Income | 144.3M | 65.7M | 92.0M | 99.3M | 44.2M |
| Interest Expense | 159.3K | 164.0K | — | 144.0K | 157.0K |
| Net Interest Income | 144.2M | 65.5M | 92.0M | 99.1M | 44.0M |
| Other Non-Op Income/Expense | 302.1M | 124.4M | (5.5M) | 155.5M | 29.1M |
| Non-Operating Income (excl Interest) | (63.9M) | 774.0K | 109.2M | (155.6M) | (24.9M) |
| EBT (Pre-Tax Income) | (849.9M) | (359.4M) | (300.9M) | (144.7M) | (314.8M) |
| Income Tax Expense | 604.1K | 506.0K | — | — | 51.9M |
| Bottom Line | |||||
| Net Income | (850.5M) | (359.9M) | (300.9M) | (144.7M) | (314.8M) |
| Earnings from Cont. Ops | (850.5M) | (359.9M) | (300.9M) | (144.7M) | (314.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (850.5M) | (359.9M) | (300.9M) | (144.7M) | (314.8M) |
| Per Share | |||||
| Basic EPS | (HK$0.85) | (HK$0.37) | (HK$0.30) | (HK$0.13) | (HK$0.29) |
| Diluted EPS | (HK$0.85) | (HK$0.37) | (HK$0.30) | (HK$0.13) | (HK$0.29) |
| Revenue Per Share | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.05 | HK$0.05 |
| Shares | |||||
| Basic Shares Outstanding | 1.0B | 972.5M | 1.0B | 1.1B | 1.1B |
| Diluted Shares Outstanding | 1.0B | 972.5M | 1.0B | 1.1B | 1.1B |
| Profitability Metrics | |||||
| EBITDA | (1.1B) | (471.6M) | (390.4M) | (126.1M) | (284.5M) |
| D&A | 27.6M | 12.9M | 14.2M | 18.5M | 30.2M |
| EBIT | (1.1B) | (484.5M) | (404.6M) | (144.6M) | (314.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026